| 16.02 1.97 (14.02%) | 04-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.95 |
1-year : | 22.13 |
| Resists | First : | 16.22 |
Second : | 18.95 |
| Pivot price | 13.97 |
|||
| Supports | First : | 14.17 |
Second : | 12.9 |
| MAs | MA(5) : | 14.13 |
MA(20) : | 14.02 |
| MA(100) : | 14.03 |
MA(250) : | 16.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 53 |
D(3) : | 35.7 |
| RSI | RSI(14): 65.2 |
|||
| 52-week | High : | 97.53 | Low : | 6.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JBIO ] has closed Bollinger Bands are 26.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.25 - 16.33 | 16.33 - 16.4 |
| Low: | 13.76 - 13.84 | 13.84 - 13.91 |
| Close: | 15.87 - 16.02 | 16.02 - 16.15 |
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Mon, 30 Mar 2026
Jade Biosciences (JBIO) price target increased by 16.48% to 26.14 - msn.com
Sat, 28 Mar 2026
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth - finance.yahoo.com
Wed, 25 Mar 2026
JBIO Analyst Rating Update: HC Wainwright Raises Price Target to $35 | JBIO Stock News - GuruFocus
Sun, 22 Mar 2026
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Mon, 16 Mar 2026
Jade Biosciences (NASDAQ:JBIO) Shares Gap Up After Analyst Upgrade - MarketBeat
Tue, 10 Mar 2026
Jade Biosciences (NASDAQ:JBIO) Raised to "Strong-Buy" at William Blair - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 101.9 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,560 (K) |
| EPS | -3.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.6 % |
| Return on Equity (ttm) | -89.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -5.03 |
| PEG Ratio | 0 |
| Price to Book value | 2.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.35 |
| Dividend | 2.4 |
| Forward Dividend | 0 |
| Dividend Yield | 14.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|